The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time

BASF’s 2025 report card, released on February 27, does not look disastrous — but it is far from comfortable. Group sales came in at €59.657 billion, down 2.9% year on year; EBITDA before special items fell 9.5% to €6.554 billion. If one stares only at these headline figures, the easy conclusion is that “the chemical cycle remains weak.” That is true — but it is also too shallow.

The deeper reality is this: BASF is pushing two major efforts in parallel — something large chemical conglomerates rarely execute at full speed at the same time. On one side, it is splitting, divesting, and restructuring to reduce legacy weight; on the other, it is holding the line on cash flow and investment rhythm to avoid being dragged deeper into the cycle. The company did not see the Q4 improvement it had hoped for, and management acknowledged that openly.

Start with why sales declined. BASF was direct in its reporting: negative currency effects were driven mainly by the U.S. dollar, the Chinese renminbi, and the Brazilian real, while fierce competition forced price reductions across almost all business lines. Only Surface Technologies and Nutrition & Care achieved year-on-year price increases. The implication is clear: BASF was not “unable to sell” in 2025 — it was selling into a tougher market, at lower prices, and converting those sales into fewer euros. That is a more punishing situation than it sounds, because it means even strong effort on volumes does not easily pull the income statement back toward a high point.

On volumes, BASF did not simply sit still. Surface Technologies delivered strong volume growth, and Agricultural Solutions and Materials posted slight volume increases. These gains fully offset volume declines in Nutrition & Care, Industrial Solutions, and Chemicals. The picture is therefore less like a broad collapse and more like structural chill: parts of the automotive-linked chain still showed resilience in certain regions, and Agricultural Solutions helped support the base, while weak pricing and industrial demand continued to weigh on overall profitability.

What dragged perception lower was the large block of special items. EBITDA in 2025 was €5.618 billion, down 9.5%, while special items in EBITDA totaled negative €936 million. Within that, restructuring charges were €937 million, mainly tied to ongoing cost-saving programs — especially those focused on the Ludwigshafen site. These figures are easy to overlook, but they often reveal the clearest management stance: when a company is willing to book such a large restructuring bill in one go, it is signaling it no longer believes it can simply “wait two years for the cycle to return.” It is choosing to take pain now and push its future cost curve down.

That leads to the central keyword in BASF’s 2025 story: cost cutting is moving faster — and hitting harder — than many expected. BASF disclosed that by the end of 2025 it had achieved roughly €1.7 billion in annual run-rate savings, raised its 2026 target from €2.1 billion to €2.3 billion, and expects total one-off costs of about €1.9 billion. This is classic “accept what you cannot control, and maximize everything you can” execution.

The price of doing that at scale tends to show up in the organization. BASF reported 108,251 employees at year-end 2025, down 3,571 from the prior year. It also disclosed that between December 2023 and December 2025, senior management positions were reduced by 11%, and headcount fell by about 4,800 employees, excluding roughly 1,000 new hires at the integrated site in China. This is not incremental optimization. It is an organizational operation designed to make a very large ship turn. Chemicals companies fear complexity, slow decision chains, and rigid cost bases — and BASF is clearly cutting into those pain points directly.

BASF was equally candid about cash flow. Cash flow from operating activities was €5.6 billion in 2025, €1.3 billion lower than the prior year. The company noted that changes in precious-metal trading positions tied up significant funds. At the same time, lower capital expenditures supported a sharp improvement in free cash flow: €1.3 billion in 2025 versus €748 million in 2024. In other words, BASF is telling the market: the P&L is under pressure, but the balance sheet and cash discipline have not broken — and are being actively repaired.

The most easily misunderstood figure in 2025 was net income. BASF reported net profit of €1.619 billion, up 24.7% year on year. That sounds like “BASF held up.” But the drivers were not a sudden revival in core chemical profitability. They were stronger equity-accounted earnings and special gains linked to Wintershall Dea. BASF disclosed around €1.3 billion of special net income in 2025, largely related to compensation under a German federal government guarantee following the expropriation of Wintershall Dea assets in Russia. Put plainly: this improved optics at the financial line, but it was not a natural recovery of the chemical cycle.

If BASF’s 2025 portrait must be compressed into one sentence, it would be this: core operations are still being pressed by the cycle, but the company is choosing heavier restructuring and faster portfolio moves to pre-empt future difficulty.

The most tangible portfolio move — and the one most likely to shape capital-market narratives — is the separation of its coatings business. In October 2025, BASF signed a binding agreement with Carlyle covering Automotive OEM Coatings, Automotive Refinish Coatings, and Surface Treatment. The transaction values the business at €7.7 billion, is expected to close in Q2 2026, and would deliver about €5.8 billion in pre-tax cash proceeds to BASF, while leaving BASF with a 40% stake in the newly created coatings entity. The structure is notably pragmatic: BASF secures meaningful cash while keeping participation in any long-term upside.

BASF also applied clean accounting treatment: the coatings units were classified as discontinued operations under IFRS 5 from September 30, 2025 onward, meaning sales and profit from that date are no longer included in BASF Group or Surface Technologies segment sales and EBIT(DA). That will make future segment comparisons cleaner — and makes it easier for management to communicate which businesses remain core and which are being repositioned as capital-managed assets.

From a wider angle, BASF’s moves fit a familiar European chemical “self-rescue” pattern. When energy costs, currency swings, and global competition erode the advantages of basic chemicals in Europe, large players tend to push in three directions at once. First, simplify the organization to lighten the cost base. Second, shift the portfolio toward higher-value, more customer-proximate, more defensible businesses. Third, use divestments or capital partners to move capital-intensive assets with slower returns off the balance sheet.

BASF’s 2026 guidance reflects a cautious but not passive stance. EBITDA before special items is expected at €6.2–€7.0 billion (€6.6 billion in 2025), while free cash flow is guided at €1.5–€2.3 billion (€1.3 billion in 2025). The range is wide, signaling management is not making aggressive promises about a rapid rebound. But the higher free-cash-flow ambition reads like a floor statement: whatever the market does, cash must be steadier.

To make the “profit under pressure but cash improving, restructuring accelerating but portfolio becoming lighter” picture more visible, the key indicators can be lined up as follows:

Once the table is read end-to-end, BASF’s 2025 “anti-intuition” becomes easier to grasp. Profitability declined, pricing stayed under pressure, currency winds blew against it — yet the company did not retreat into pure defense. Instead, it chose faster restructuring and more decisive portfolio adjustment to create future room to move. That is also why management repeatedly emphasized focusing on controllable actions within its strategic framework: when the uncontrollable grows, the only viable response is to execute the controllable at maximum intensity.

One sharper closing point: BASF’s real turning point in 2025 was not the income statement. It was resolve. The company is increasingly managing itself in a private-equity-like way: sell what should be sold, partner what should be partnered, cut what should be cut, and prioritize cash and structural change over “good-looking growth.” If markets remain weak in the first half of 2026, that decision will matter even more — because at the bottom of a cycle, the companies that last longer are usually the ones that get to talk about the next expansion.